Koning Breast Computed Tomography Guided Neoadjuvant Treatment Monitoring
|ClinicalTrials.gov Identifier: NCT01771497|
Recruitment Status : Completed
First Posted : January 18, 2013
Last Update Posted : January 13, 2016
|Condition or disease||Intervention/treatment|
|Breast Cancer||Device: Koning Breast CT|
|Study Type :||Observational|
|Actual Enrollment :||12 participants|
|Official Title:||Koning Breast CT (KBCT)-Guided Neoadjuvant Treatment of Breast Cancer Monitoring Phase I Trial|
|Study Start Date :||July 2010|
|Actual Primary Completion Date :||December 2015|
|Actual Study Completion Date :||December 2015|
|Women undergoing neoadjuvant therapy||
Device: Koning Breast CT
Koning Breast CT scans will be assessed at the beginning, mid-point and end of therapy.
Other Name: Dedicated breast CT
- Tumor volume change from baseline during neoadjuvant treatment [ Time Frame: Baseline, mid-point (~3 months), and end of therapy (4-6 months) ]
Tumor volume will be measured with KBCT imaging at the beginning of the therapy (baseline), mid-point of the therapy (about 3 months after the treatment starts) and end of therapy (about 4-6 months after the treatment starts). The volume change from the baseline during the treatment will be recorded.
Adverse Events will be recorded as a measure of safety.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01771497
|United States, New York|
|University of Rochester Medical Center Highland Breast Imaging Center|
|Rochester, New York, United States, 14623|